Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Curr Drug Metab. 2021;22(9):735–745. doi: 10.2174/1389200222666210831125041

Fig. (3).

Fig. (3).

Metabolomic analysis of GA-607-versus vehicle-treated EL4 tumors. GA-607 treatment caused an increase in FGAR, glucose, glutamine, and uridine 5′-diphospho-N-acetylglucosamine in the tumor and a decrease in succinate, aspartate, and nucleotide diphosphates.